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^valuation of the Economic Impact of Pharmacist Involvement
- "tents in Hyperalimentation Therapy
• assess.

Larry Crots, RPh,* and Larry Shoup, MS^
A prospective parallel study of patients receiving total parenteral nutrition (TPN) was undertaken to
identify characteristics of TPN solution use and wasle. Thirty consecutive patients receiving TPN by
order ofthe primary chnical service (control group) were compared with 25 consecutive patients
receiving TPN under the supervision and monitoring of the Nutritional Support Service (study group).
The patients were evenly divided between medical and .surgical problems, with 53% of the control
group being surgical patients compared to 56% ofthe study group. There were 136 L of TPN or 4.5
Upatient discarded in the control group compared to 65 Lor 2.6 L/patient discarded in the study
group. This wastage expressed as a percentage is 13.2% for the control group and 7.1% for the study
group. Pharmacist involvement in TPN monitoring and supervision was associaied with a 46%
decrease in solution waste. The data from this study suggest that pharmacist involvement in TPN
monitoring and supervision may be cost-effective. (Henry Ford Hosp Med J 1986;34:99-100)

arenteral nutrition solutions constitute a major component
ofthe cost of total parenteral nutrition (TPN) therapy (1). As
an integral member of the nutritional support team, the pharmacist is uniquely qualified to assist in maximizing the effective
use and minimizing the waste of TPN solutions. The impact of
pharmacist monitoring of TFN usage to help decrease waste is
not well known (2,3). This prospective study was undertaken to
determine the effect of pharmacists' monitoring of TPN solution
use.

P

Materials and Methods
Beginning in July 1982, during a three-month period, 30 consecutive patients receiving TPN by order of the primary clinical
service (control group) were identified and compared to 25 consecutive patients receiving TPN under supervision and monitoring of the nutritional support team (study group). These two
groups were compared in terms of TPN solution use and waste.
The TPN team pharmacist actively participated in planning
and monitoring therapy for the 25 study group patients. The
pharmacist was attentive to activities which would promote effective ordering and use of TPN solutions while decreasing the
number of solutions that were prepared but not administered.
Examples of these activities include the following:
1. Physicians were encouraged to correct electrolyte imbalances by adjusting peripheral intravenous (IV) therapy or
enteral therapy rather than changing already prepared TPN
solutions.
2. Physicians were encouraged to alter future TPN solution
formulations with the next solution to be infused.
3. The inpatient pharmacy was promptly notified of solution
changes to decrease unnecessary solution preparation.
4. Clinical and laboratory data were monitored to anticipate
"•equired changes in formulation.
5. Altematives to parenteral nutrition were suggested when
appropriate.
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Results
The results of this prospective study are summarized in the
Table. Demographically, the control and study group patients
were similar. Both groups also had similar courses of TPN
therapy.
The Table illustrates substantial differences between the two
groups in liters of TPN solution discarded during therapy. In the
control group, 136 L of TPN or 4.5 L/patient were discarded
compared to 65 L of TPN or 2.6 L/patient in the study group.
The percentage waste (total liters wasted divided by total liters
infused) was 13.2% for the control group and 7.1% for the study
group. Of the parenteral nutrition regimens prescribed, ten of
the 30 patients (33%) in the control group utilized peripheral hyperalimentation. In the study group, three of the 25 patients
(12%) utilized peripheral hyperalimentation, which was a 21%
reduction in peripheral hyperalimentation use.
Wastage of TPN solutions in primary service administration
(control group) was high, 4.5 L of TPN solution per patient.
Expressed as dollars, based on a manufacturer's list price of
$46.71/L, this loss averaged $210.20/patient in solution costs
alone. In the study group only 2.6 L/patient of TPN solution
were wasted. The difference between the control and study
groups amounted to $93.43/patient.

Discussion
Nutritional support is expensive, particularly in the form of
parenteral nutrition. In 1982, approximately 450 Henry Ford
Hospital patients received this form of therapy at an average
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Table
Suinmary Comparison of Control and Study Groups
(Demographics and TPN Use and Waste)
Number of patients
Patient age
Average years (range)
Sex: male/female
Primary service (No. of patients)
Medicine
Surgery
Duration of TPN therapy
Average (days)
Range
Liters of TPN infused
Total
Average/patient
Range
Liters wasted
Total
Average/patient
% Wastage
(Total unused/total infused)
% Peripheral hyperalimentation

annual retail cost of $815,000 per year. The estimate that approximately $1 billion were spent in the United States in 1985
for solutions and equipment illustrates this costly therapeutic
modality (4).
Since most cases referred to the nutritional support team are
complicated and beyond their DRG cash allotment, nutritional
support teams are facing an economic pressure to disband. The
argument for keeping the team relies on the proven safety and
efficacy of nutritional support when managed according to
protocol. Complications and waste associated with overfeeding, underfeeding, or inappropriate feeding may result in cost
increases that far outweigh the cost of the team (5).
In this study pharmacist involvement in TPN monitoring and
supervision was associated with a 46% decrease in central venous solution waste compared to the control group. This reduction in solution waste when calculated on 450 patients amounts
to $79,874 per yean This improved efficiency of solution use
was accomplished with careful attention to needed changes in
therapy and a thorough understanding of formulation schedules
in the pharmacy.
The 21% reduction of peripheral hyperalimentation use was
accomplished in two ways: 1) by using the gastrointestinal tract
when possible with tube feedings and/or oral supplements rather
than peripheral therapy, or 2) by instituting central venous hyperalimentation if the duration of therapy warranted a prolonged
course of IV nutritional support longer than ten days. The cost
difference in central venous hyperalimentation and peripheral
hyperalimentation is approximately $34.68 per day. This addi-

Control Group
30

Study Group
25

60.8 (22 to 92)
21/9

50.6 (15 to 75)
17/8

14
1(1

11
14

13.1
5 to 34

13.4
6 to 24

1,029
34.3
12 to 90

920
36.8
16 to 60

1 36
4.5

2.6

13.2%
33.3%

7.1%
12%

(i.-s

tional cost, applied to 33% of 450 patients, amounts to $67,175
per year The peripheral venous route is a more expensive mode
of therapy because of the extensive use of IV fat emulsions as a
primary caloric source. Based on retail costs of hyperalimentation solutions, pharmacist intervention in these few areas could
reduce costs by approximately $122,700 per year. Thus, the
pharmacist's role in this area of therapeutic management is beneficial on both clinical and economic grounds (6-8).
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